{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T18:13:48Z","timestamp":1765995228996,"version":"3.41.2"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The current prevalence and clinical burden of Hepatitis Delta Virus (HDV) infection in Apulia are unknown. This study aimed to define the current epidemiological scenario of delta infection and to detect difficulties in the diagnosis and clinical management of HDV patients in Apulia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>From May to September 2022, a fact-finding survey was conducted at eight Infectious Diseases Units of the Apulian region; each Unit was asked to complete a questionnaire on screening and diagnosis of HDV infection and demographic, virological, and clinical characteristics of HDV patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 1,461 HBsAg-positive subjects were followed up on an outpatient basis. Screening for HDV ranged from 30 to 90% of HBsAg + carriers in a single center. Overall, 952 HBsAg \u00b1 subjects (65%) were tested for HDV, and 80\/952 (8.4%) were anti-HDV positive. Serum HDV RNA was detected only in 15\/80 (19%) anti-HDV-positive subjects, and 12\/15 patients (80%) were viremic. Sixty-five anti-HDV-positive subjects (81%) were from Italy; risk factors for HDV acquisition included the presence of HDV infection in the family (29\/80 = 36%), drug addiction (12\/80 = 15%), and co-infection with HCV or HIV (7\/80 = 9%). Liver cirrhosis and hepatocellular carcinoma were diagnosed in 41 (51%) and 4 (5%) patients, respectively. Fifty-seven patients (71%) received nucleos(t)ide analog treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The results of this survey show that HDV screening is variable and insufficient, thus real prevalence data on delta infection are lacking in Apulia. Moreover, the HDV RNA test is not available in most laboratories and is not provided by the national health system. These results underline the need for an organizational model to optimize the management of HDV patients throughout the Apulian region.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2023.1247454","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T10:16:52Z","timestamp":1695809812000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Apulian infectious diseases network: survey on the prevalence of delta infection among chronic HBV carriers in Apulia"],"prefix":"10.3389","volume":"11","author":[{"given":"Massimo","family":"Fasano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Milella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Carbonara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Tundo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Minniti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Buccoliero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Maria","family":"Maci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Lo Caputo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa Antonia","family":"Santantonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1056\/NEJMra2212151","article-title":"Hepatitis D virus infection","volume":"389","author":"Asselah","year":"2023","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/apt.15188","article-title":"Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir","volume":"49","author":"Brancaccio","year":"2019","journal-title":"Aliment Pharmacol Therapeut"},{"key":"B3","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3390\/v13040555","article-title":"Forty-five years after the discovery of the hepatitis D virus: where do we stand?","volume":"13","author":"Rizzetto","year":"2021","journal-title":"Viruses."},{"key":"B5","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/jvh.13310","article-title":"Migratory flow and hepatitis delta infection in Italy: a new challenge at the beginning of the third millennium","volume":"27","author":"Stroffolini","year":"2020","journal-title":"J Viral Hepat"},{"key":"B6","doi-asserted-by":"publisher","first-page":"S1082","DOI":"10.1016\/S0168-8278(23)03188-4","article-title":"Epidemiological and clinical profile of HDV infected people in care in Italy: interim analysis from the ongoing PITER cohort","volume":"78","author":"Kondili","year":"2023","journal-title":"J Hepatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ijid.2023.02.006","article-title":"Trends in chronic hepatitis B virus infection in Italy over a 10-year period: clues from the nationwide PITER and MASTER cohorts toward elimination","volume":"129","author":"Brancaccio","year":"2023","journal-title":"Int J Infect Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/liv.15389","article-title":"Bulevirtide for patients with compensated chronic hepatitis delta: a review","volume":"43","author":"Degasperi","year":"2022","journal-title":"Liver Int"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1016\/j.jhep.2022.06.010","article-title":"Bulevirtide with or without pegifn\u03b1 for patients with compensated chronic hepatitis delta: from clinical trials to real-world studies","volume":"77","author":"Lampertico","year":"2022","journal-title":"J Hepatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa2213429","article-title":"A phase 3, randomized trial of bulevirtide in chronic hepatitis D","volume":"389","author":"Wedemeyer","year":"2023","journal-title":"N Engl J Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jhep.2023.05.001","article-title":"EASL clinical practice guidelines on hepatitis delta virus","volume":"79","year":"2023","journal-title":"J Hepatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"104932","DOI":"10.1016\/j.jcv.2021.104932","article-title":"Reliable quantification of plasma HDV RNA is of paramount importance for treatment monitoring: a European multicenter study","volume":"142","author":"Stelzl","year":"2021","journal-title":"J Clin Virol."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1247454\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T10:16:54Z","timestamp":1695809814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2023.1247454\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,26]]},"references-count":12,"alternative-id":["10.3389\/fpubh.2023.1247454"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2023.1247454","relation":{},"ISSN":["2296-2565"],"issn-type":[{"type":"electronic","value":"2296-2565"}],"subject":[],"published":{"date-parts":[[2023,9,26]]},"article-number":"1247454"}}